News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Pharmacyclics, Inc. Reports Interim Phase II Trial Results for BTK Inhibitor PCI-32765 in Mantle Cell Lymphoma at American Society of Hematology (ASH) Annual Meeting
December 12, 2011
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Twitter
LinkedIn
Facebook
Email
Print
Events
MORE ON THIS TOPIC
Sickle cell disease
Vertex, Beam Report SCD Cell and Gene Therapies Advances at ASH 2024
December 9, 2024
·
2 min read
·
Tristan Manalac
Bladder cancer
Protara, CG Oncology Tout Promising Bladder Cancer Outcomes
December 6, 2024
·
2 min read
·
Tristan Manalac
Cancer
AstraZeneca/Daiichi Sankyo, BioNTech, Merus to Present Promising Cancer Therapies at ESMO Asia 2024
December 2, 2024
·
4 min read
·
Tristan Manalac
MASH
Novo, Viking Heat Up MASH Space with Promising Data at AASLD24
November 20, 2024
·
3 min read
·
Tristan Manalac
